Effect of Lactobacillus plantarum IS-10506 supplementation with oral metronidazole for the treatment of bacterial vaginosis : a randomized placebo-controlled clinical trial
DOI:
https://doi.org/10.66344/jpad.32.4.2022.2005Abstract
Background: Replacement of Lactobacillus spp. by anaerobic and facultative bacteria is central in pathogenesis of bacterial vaginosis (BV). Oral metronidazole is currently recommended treatment. However, cure rate is variable. Probiotic supplementation was explored as alternative therapy. This study aimed to find out the effect of oral microencapsulated Lactobacillus plantarum IS-10506 supplementation on oral metronidazole 500 mg twice daily for the treatment of BV. Methods: Twenty nine females with BV were treated with oral metronidazole and randomized into probiotic (Pro) (n=14) and placebo (Pla) (n=15) groups. Pro group received microencapsulated L. plantarum IS-10506 supplementation at 0.9x109 CFU, twice daily. Pla group received placebo twice daily. Cure is defined from Amsel criteria and Nugent score 0-3. Metronidazole was stopped if subjects were cured. Probotic and placebo were continued for 4 weeks. Cure rate and mean Nugent score were assessed at baseline, end of week 1, 2 and 4. Results: Mean Nugent score for Pro against Pla group were 8.07 vs. 8.07, 5.36 vs. 6.20, 4.07 vs. 4.93, and 3.57 vs. 4.33 respectively at baseline, end of week 1, 2 and 4. Cure rate for Pro against Pla group were 28.6% vs 20.0%, 50.0% vs 33.3%, 64.3% vs 40.0% respectively at end of week 1, 2 and 4. Mean Nugent score significantly decreased in both groups at end of week 1, 2 and 4 (p£ 0.05). Although not statistically significant, mean Nugent score was lower and cure rate was higher in Pro than Pla group at end of week 1, 2 and 4 (p>0.05). No adverse effects was recorded. Conclusions: Oral probiotic L. plantarum IS-10506 supplementation in addition to oral metronidazole were safe and potentially better than oral metronidazole alone for treatment of BV. Studies with longer probiotic supplementation and more subjects may be required to demonstrate significant effect of this combination treatment on BV.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
